Factories For Sale As Roche's Modernization Drives Site Closures
This article was originally published in Scrip
Roche Holding AG will cease manufacturing at four sites in Europe and the US in a modernizing move that could see up to 1,200 jobs lost as a result of changes in the cancer specialist's portfolio of therapies. The decision follows a review of Roche's global manufacturing network for small molecules and an assessment of future drug innovation patterns.
You may also be interested in...
Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.
Novo Nordisk and Evotec will identify and develop novel drugs for treating chronic kidney disease, using datasets of CKD patients provided by the Danish group and from other sources.
Sanofi is paying for $3.68bn cash for Principia to get the US biotech’s drug development platform and nascent pipeline, including a brain-penetrant BTK inhibitor in Phase III for multiple sclerosis.